Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zeynep Eroglu

Showing results (71-80 of 116) with videos related to

Pageof 12
Sort By:
Journal for Immunotherapy of Cancer|March 8, 2023
Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapyPrachi Bhave, Angela Hong, Serigne N Lo, et al.
Journal for Immunotherapy of Cancer|November 30, 2022
Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanomaNikhil I Khushalani, Melinda Vassallo, Judith D Goldberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2021
Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal MetastasesInna Smalley, Zhihua Chen, Manali Phadke, et al.
JCO Oncology Practice|June 23, 2026
Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 TherapyMegan Othus, Thach-Giao Truong, Elad Sharon, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2017
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanomaLisa Zimmer, Susmitha Apuri, Zeynep Eroglu, et al.
Journal for Immunotherapy of Cancer|January 14, 2026
Neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma: an investigator-initiated, open-label phase II trialAndrew S Brohl, Vernon K Sondak, Evan J Wuthrick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2024
Neoadjuvant Intratumoral Plasmid IL-12 Electro-Gene-Transfer and Nivolumab in Patients with Operable, Locoregionally Advanced MelanomaAhmad A Tarhini, Zeynep Eroglu, Islam Eljilany, et al.
Melanoma Research|September 27, 2022
Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case seriesJessica Louise Smith, Alexander M Menzies, Justine V Cohen, et al.
Cancer Immunology Research|March 3, 2021
Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor ImmunityManali S Phadke, Zhihua Chen, Jiannong Li, et al.
Cancer|August 18, 2016
The efficacy of anti-PD-1 agents in acral and mucosal melanomaAlexander N Shoushtari, Rodrigo R Munhoz, Deborah Kuk, et al.
Pageof 12

Showing results (71-80 of 116) with videos related to

Sort By:
Pageof 12
Journal for Immunotherapy of Cancer|March 8, 2023
Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapyPrachi Bhave, Angela Hong, Serigne N Lo, et al.
Journal for Immunotherapy of Cancer|November 30, 2022
Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanomaNikhil I Khushalani, Melinda Vassallo, Judith D Goldberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 26, 2021
Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal MetastasesInna Smalley, Zhihua Chen, Manali Phadke, et al.
JCO Oncology Practice|June 23, 2026
Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 TherapyMegan Othus, Thach-Giao Truong, Elad Sharon, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2017
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanomaLisa Zimmer, Susmitha Apuri, Zeynep Eroglu, et al.
Journal for Immunotherapy of Cancer|January 14, 2026
Neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma: an investigator-initiated, open-label phase II trialAndrew S Brohl, Vernon K Sondak, Evan J Wuthrick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2024
Neoadjuvant Intratumoral Plasmid IL-12 Electro-Gene-Transfer and Nivolumab in Patients with Operable, Locoregionally Advanced MelanomaAhmad A Tarhini, Zeynep Eroglu, Islam Eljilany, et al.
Melanoma Research|September 27, 2022
Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case seriesJessica Louise Smith, Alexander M Menzies, Justine V Cohen, et al.
Cancer Immunology Research|March 3, 2021
Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor ImmunityManali S Phadke, Zhihua Chen, Jiannong Li, et al.
Cancer|August 18, 2016
The efficacy of anti-PD-1 agents in acral and mucosal melanomaAlexander N Shoushtari, Rodrigo R Munhoz, Deborah Kuk, et al.
Pageof 12